Oxford Biomedica plc

LSE:OXB Stock Report

Market Cap: UK£446.5m

Oxford Biomedica Future Growth

Future criteria checks 5/6

Oxford Biomedica is forecast to grow earnings and revenue by 92.5% and 21.2% per annum respectively. EPS is expected to grow by 99% per annum. Return on equity is forecast to be -21.4% in 3 years.

Key information

92.5%

Earnings growth rate

99.0%

EPS growth rate

Biotechs earnings growth34.5%
Revenue growth rate21.2%
Future return on equity-21.4%
Analyst coverage

Good

Last updated03 Dec 2024

Recent future growth updates

Recent updates

Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

Oct 19
Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

Aug 23
Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 15
Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value

Is Oxford Biomedica (LON:OXB) Using Too Much Debt?

Oct 06
Is Oxford Biomedica (LON:OXB) Using Too Much Debt?

Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings

May 02
Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings

We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn

Jun 29
We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn

Earnings and Revenue Growth Forecasts

LSE:OXB - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026213823318
12/31/2025167-17-138
12/31/2024129-38-26-268
6/30/202497-142-72-62N/A
3/31/202493-150-55-45N/A
12/31/202390-157-38-29N/A
9/30/2023104-110-24-11N/A
6/30/2023119-62-96N/A
3/31/2023130-50-19-3N/A
12/31/2022140-39-29-13N/A
9/30/2022133-32-31-17N/A
6/30/2022126-25-33-21N/A
3/31/2022134-3-92N/A
12/31/2021143191625N/A
9/30/2021139191526N/A
6/30/2021135191526N/A
3/31/20211116215N/A
12/31/202088-6-103N/A
9/30/202077-9-16-1N/A
6/30/202066-13-22-6N/A
3/31/202065-14-26-5N/A
12/31/201964-16-29-4N/A
9/30/201964-12-26-4N/A
6/30/201964-8-23-4N/A
3/31/2019650-104N/A
12/31/2018678313N/A
9/30/2018624918N/A
6/30/20185701623N/A
3/31/201847-5N/A13N/A
12/31/201738-9N/A3N/A
9/30/201734-10N/A-1N/A
6/30/201731-11N/A-6N/A
3/31/201729-14N/A-4N/A
12/31/201628-17N/A-2N/A
9/30/201626-16N/A-1N/A
6/30/201624-16N/A-1N/A
3/31/201620-15N/A-7N/A
12/31/201516-13N/A-13N/A
9/30/201515-12N/A-12N/A
6/30/201513-10N/A-10N/A
3/31/201513-9N/A-8N/A
12/31/201414-9N/A-6N/A
9/30/201411-9N/A-8N/A
6/30/20148-10N/A-9N/A
3/31/20147-11N/A-10N/A
12/31/20135-11N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OXB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: OXB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OXB is expected to become profitable in the next 3 years.

Revenue vs Market: OXB's revenue (21.2% per year) is forecast to grow faster than the UK market (3.6% per year).

High Growth Revenue: OXB's revenue (21.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: OXB is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 02:56
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oxford Biomedica plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rick BienkowskiCantor Fitzgerald & Co.
Susie JanaEdison Investment Research
Jens LindqvistInvestec Bank plc (UK)